Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 495 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alzamend Neuro Inc | ALZN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0035 | 0.56% | 0.6235 | 07:35:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.62 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 3 | 495 | - | 0.4388 - 11.91 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:10:36 | 1 | US$ 0.5601 | USD |
Alzamend Neuro Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.41M | 7.12M | - | 0 | -14.88M | -2.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alzamend Neuro News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/22/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/22/2024 | 07:00 | Business Wire | Alzamend Neuro Announces Favorable Decision from Nasdaq.. |
| 5/16/2024 | 15:30 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership.. |
| 5/14/2024 | 07:00 | Business Wire | Alzamend Neuro Announces Initial Closing of Private.. |
| 5/13/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/10/2024 | 16:06 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 5/10/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
| 5/10/2024 | 05:30 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 5/09/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/09/2024 | 15:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/09/2024 | 07:00 | Business Wire | Alzamend Neuro Announces Agreement for Registered Direct.. |
| 5/07/2024 | 15:31 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALZN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.62 | 0.68 | 0.60 | 0.6362782 | 46,199 | 0.0035 | 0.56% |
| 1 Month | 0.72 | 0.78 | 0.4388 | 0.5955156 | 104,663 | -0.0965 | -13.40% |
| 3 Months | 0.94 | 1.29 | 0.4388 | 0.840333 | 86,152 | -0.3165 | -33.67% |
| 6 Months | 1.11 | 1.29 | 0.4388 | 0.8981413 | 69,125 | -0.4865 | -43.83% |
| 1 Year | 7.8585 | 11.91 | 0.4388 | 3.85 | 150,719 | -7.24 | -92.07% |
| 3 Years | 435.00 | 503.25 | 0.4388 | 41.89 | 1,189,501 | -434.38 | -99.86% |
| 5 Years | 435.00 | 503.25 | 0.4388 | 41.89 | 1,189,501 | -434.38 | -99.86% |
Alzamend Neuro Description
| Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. |
